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The Journal of Immunology
Secretory Leukocyte Proteinase Inhibitor-Competent DNA
Deposits Are Potent Stimulators of Plasmacytoid Dendritic
Cells: Implication for Psoriasis
Joanna Skrzeczynska-Moncznik,*,1 Agnieszka Wlodarczyk,*,1 Katarzyna Zabieglo,*
Monika Kapinska-Mrowiecka,† Ewa Marewicz,* Adam Dubin,‡ Jan Potempa,x,{ and
Joanna Cichy*
Secretory leukocyte proteinase inhibitor (SLPI) is a well-established inhibitor of serine proteases such as human neutrophil elastase
(HNE) and a NF-kB regulatory agent in immune cells. In this paper, we report that SLPI plays a previously uncharacterized role
in regulating activation of plasmacytoid dendritic cells (pDCs). As the main source of IFN type I (IFNI), pDCs are crucial
contributors to inflammatory and likely wound-healing responses associated with psoriasis. The mechanisms responsible for
activation of pDCs in psoriatic skin are therefore of substantial interest. We demonstrate that in lesional skin of psoriasis patients,
SLPI together with its enzymatic target HNE and DNA, is a component of neutrophil extracellular traps (NETs). Whereas SLPI+
neutrophils and NETs were found to colocalize with pDCs in psoriatic skin, a mixture of SLPI with neutrophil DNA and HNE
induced a marked production of IFNI by pDCs. IFNI synthesis by stimulated pDCs was dependent on intracellular DNA receptor
TLR9. Thus, SLPI may contribute to psoriasis by enabling pDCs to sense extracellular DNA and produce IFNI. The Journal of
Immunology, 2012, 189: 1611–1617.
S
ecretory leukocyte proteinase inhibitor (SLPI), a cationic
protein of ∼12 kDa, was first described as a potent in-
hibitor of serine proteinases, including human neutrophil
elastase (HNE) and cathepsin G (CatG) (1). SLPI is expressed
by several cell types including epithelia, macrophages, and neu-
trophils (2–5). As one of the major agents controlling serine
protease activity, SLPI is thought to play an important role in
limiting protease-mediated tissue injury associated with inflam-
mation, especially at mucosal/epithelial surfaces, as well as in
wound healing (6, 7). However, its protective anti-inflammatory
role is not restricted to antiprotease defense, because SLPI also
exhibits antimicrobial properties and immunomodulatory activity
(1). The latter is based on the ability of SLPI to interfere with the
activation of transcription factor NF-kB (8, 9). Engagement of the
NF-kB signaling pathway culminates in the expression of proin-
flammatory genes such as IL8 and TNF-a in LPS-activated
monocytic cells and class switch recombination in activated
B cells. Both of these NF-kB–mediated effects are inhibited by
SLPI (8, 9).
In contrast to macrophages and B cells, the role of SLPI in
neutrophils remains unknown, although a recent report suggests
that SLPI inhibits apoptosis of these cells (10). Neutrophils pro-
duce several inhibitors of serine proteases, including a1-protein-
ase inhibitor (a1-PI), human elastase inhibitor, and minor amounts
of elafin (4, 11). Nevertheless, SLPI is the major inhibitor of HNE
in neutrophils (4), suggesting an important contribution by SLPI
to HNE-mediated processes in these cells.
Neutrophils (also referred to as polymorphonuclear leukocytes
[PMNs]) play a key role in host defense against pathogens. PMNs
engulf bacteria and fuse the phagocytic compartment with cyto-
plasmic granules containing bactericidal compounds. Three types
of cytoplasmic granules have been described in neutrophils: pri-
mary HNE-containing, secondary lactoferrin-containing, and ter-
tiary gelatinase-containing granules (12). Activated neutrophils
can also eliminate microbes extracellularly by the formation of
neutrophil extracellular traps (NETs), for example. NETs, web-
like structures composed of neutrophil DNA and antibacterial
proteins, are thought to form via a unique cell death program
called NETosis (13). Although the mechanism underlying
NETosis remains largely elusive, HNE is required for chromatin
decondensation, via specific histone cleavage (14). This process
leads to cell rupture and release of NETs. The major structural
components of NETs are DNA and HNE, although several other
granular proteins have also been identified in the superstructure
(15). We hypothesized that SLPI, as a controlling inhibitor of
HNE, is a NET component as well.
Interestingly, in autoimmune and autoimmune-like diseases such
as systemic lupus erythematosus (SLE), small-vessel vasculitis,
and psoriasis, neutrophil accumulation is often common in affected
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sites in the absence of bacterial infection. Neutrophil migration
into psoriatic skin, first observed as perivascular accumulation, is
followed by an influx into the epidermis where it often manifests
as microscopically detectable microabscesses (16). Although the
formation of NETs has been mainly associated with antimicrobial
function, recent reports suggest a role in triggering autoimmune
small-vessel disease and SLE (17–20).
Psoriasis and SLE share strong dependence on chronic activa-
tion of plasmacytoid dendritic cells (pDCs) (17, 20–22). pDCs,
a unique cell type of the DC lineage, specialize in sensing nucleic
acid “danger signals” primarily via expression of TLR7 and
TLR9, which recognize ssRNA and DNA, respectively (23). Ex-
pression of these receptors allows pDCs to uniquely respond to
viral nucleic acids by production of type I IFNs, including IFN-a
(24), abbreviated hereafter as IFNI. Although IFNI is critical in
inhibiting viral replication, activating antiviral/antimicrobial
functions of many cells, and promoting wound healing, IFNI
also plays a key role in inducing autoimmunity, including psori-
asis (22). pDCs normally do not respond to host DNA. However,
recent studies indicate that in addition to viral/microbial DNA,
self-DNA also can initiate production of IFNI in pDCs, if deliv-
ered to and retained within specific endocytic compartments to
trigger TLR9 (21). In psoriasis, the delivery of self-DNA to spe-
cific endosomes is reported to require coupling of the DNA to
an antimicrobial peptide of the cathelicidin family of proteins,
LL37 (21). LL37 is mainly produced by epidermal keratinocytes
(21). Another possible source of LL37 is neutrophils (25, 26).
Keratinocyte-derived LL37 is unlikely to be solely responsible for
delivery of host DNA to TLR9 in pDCs, because it is mainly
detected in the epidermis, whereas pDCs primarily infiltrate the
dermis.
In this work, we demonstrate that induction of IFNI synthesis by
skin-infiltrating pDCs may depend on SLPI, because this inhibitor
is found within NETs in psoriatic skin, and together with the well-
known NET constituents DNA and HNE, strongly stimulates
production of IFNI in pDCs. Thus, our data define a novel role for
SLPI as a factor that controls the immunogenicity of extracellular
DNA in damaged skin.
Materials and Methods
Materials
Recombinant SLPI was purchased from R&D Systems. Synthetic LL37
was from Emory Microchemical Facility. HNE was isolated using fresh
whole human blood from healthy donors as a starting material, as de-
scribed previously (27). Pig pancreatic trypsin was active-site–titrated with
p-nitrophenyl guanidobenzoate (28) and used to standardize the solution of
human a1-PI. Final inhibitor preparation was more than 95% pure and
80% active. This inhibitor was then used as a secondary standard to de-
termine the activity of HNE, which was measured in 0.1 M Tris-HCl and
0.5 M NaCl (pH 7.4), using 0.5 mM MeO-Suc-Ala-Ala-Pro-Val-pNA as
a substrate. Final preparation of HNE was more than 95% pure and 90%
active. Azurocidin obtained during purification of HNE by ion exchange
in a protein pick eluded before HNE at 0.3 M NaCl was further purified
by FPLC using Pharmacia Mono S 5/5 column. Protein content in HNE
and azurocidin preparation was estimated using A280 (1%) 9.85 and 5.0,
respectively. Where indicated, serine protease inhibitor 3,4-dichlor-
oisocoumarin was used for irreversible inhibition of HNE. After intensive
dialysis such preparation of HNE with undetectable enzymatic activity was
used in experiments. Human plasma a1-PI was isolated as described
previously (29). SLPI was oxidized with 500 molar excess of N-chlor-
osuccinimide (NCS) for 1 h in room temperature at pH 8, as described
previously (30, 31). The oxidation was stopped by an addition of N-ace-
tylmethionine to final concentration of 50 mM. Oxidized SLPI was then
dialyzed against 0.15 M NaCl and tested for anti-HNE activity as de-
scribed above. The oxidation of SLPI resulted in 70% inactivation of its
anti-NE activity, an expected value for the reversible inhibitor (30, 31).
Human genomic DNA was isolated from peripheral blood neutrophils of
healthy donors using a method based on guanidine thiocyanate. Guanidine
thiocyanate lysates were extracted with phenol:chloroform. DNA was
precipitated from water phase using isopropanol and resuspended in 10
mM Tris pH 7.5, 1 mM EDTA, as described previously (32). DNA purity
measured as A260/A280 ratio was between 1.8 and 2.0.
Patients
All human studies were performed in accordance with guidelines estab-
lished by the Jagiellonian University Institutional Bioethics Committee
under approved protocols. Declaration of Helsinki protocols were followed.
A total of 13 psoriasis patients (age, 34.46 14 y; female/male, 6:9) and 16
healthy individuals (age, 28.6 6 7.3 y; female/male, 9:7) were enrolled
into these studies. The severity of the psoriatic skin lesions was assessed
according to the Psoriasis Area Severity Index score (minimum point 0,
maximum point 72) and ranged from 19.8 to 42.2 (mean 6 SD, 32 6 8.1).
Patients on UV therapy or systemic or local corticosteroid treatment were
excluded from the studies. Healthy control subjects had no clinical signs of
dermatologic diseases.
Isolation of pDCs and neutrophils
Human blood was collected and PBMC and granulocyte-enriched fractions
were harvested following LSM1077 (PAA Laboratories) gradient separa-
tion, as described by the manufacturer. pDCs were enriched from PBMC
using negative selection with biotinylated mAbs directed against CD3,
CD14, CD16, CD19, CD20, CD56, and anti-biotin MACS Microbeads
(Miltenyi Biotec), according to the manufacturer’s recommendations. Cells
were separated by magnetic sorting using an Automacs. The pDCs purity
was ∼95% as determined by CD123 and BDCA-2 immunoreactivity and
flow cytometry analysis. In selected experiments, pDCs were further pu-
rified by cell sorting based on the expression of the specific BDCA-4 Ag.
The pDCs purity was then .98%. However, because this method of pDC
purification resulted in similar data, in most experiments, we used pDCs
obtained by a negative selection.
Neutrophils were further purified from granulocyte-enriched fractions.
The high-density fraction, containing neutrophils and erythrocytes, were
mixed with a 1% solution of polyvinyl alcohol (Merck) in PBS and in-
cubated for 20 min at room temperature. Neutrophils were harvested from
the upper phase and subjected to hypotonic lysis to remove contaminating
RBCs. The purity of the isolated cells was examined by flow cytometry
based on forward light scatter and side scatter (of light) parameters and/or
HNE immunoreactivity. Granulocytes were routinely .98% pure.
pDC treatment
Purified 5 3 105 pDCs were seeded into round-bottom 96-well plates in
50–100 ml RPMI 1640 medium. The factors were either added directly into
pDC cultures or first premixed with DNA or with each other in 10–20 ml
RPMI 1640 medium. After a 15-min incubation at room temperature, the
mix was diluted 10 or 5 times and added to the pDC cultures. The fol-
lowing factors at indicated final concentration were used: HNE, inactive
HNE, azurocidine, SLPI, NCS-oxidized SLPI, a1-PI (all at 1 mM), and
LL37 at 10 mM and/or human neutrophil-derived DNA at 2 mg/ml. The
anti-HNE activity of SLPI was alternatively neutralized by 15-min incu-
bation with 10 molar excess of goat anti-human SLPI Abs (R&D Systems)
or goat IgG (Jackson ImmunoResearch Laboratories) as a control. The Abs
treatment resulted in ∼30–50% reduction of HNE inhibitory activity. SLPI
plus Abs was then incubated with HNE and DNA, followed by stimulation
of pDCs. The final concentration of the factors was 0.1–0.2 mM (SLPI and
HNE) and 0.2–0.4 mg DNA. The involvement of TLR9 in pDCs activation
was studied by treatment of pDCs with the inhibitory ODNTTAGGG or
control ODN (Invitrogen) both given at ∼4:1 ratio (ODN: HNE/SLPI/
DNA) 30 min before addition of the premixed stimuli to the pDC cul-
tures. The pDCs were then cultured at 37˚C, 5% CO2 for 24 h in RPMI
1640 medium supplemented with 10% of FBS and human recombinant
IL-3 (50 ng/ml) (Peprotech), which improves pDC survival in vitro. Con-
ditioned media were collected, centrifuged at 500 3 g for 5 min to remove
the cells, and tested by ELISA.
ELISA
IFNI levels were quantified by IFN-a–specific ELISA (PBL Interferon-
Source) according to the manufacturer’s recommendations.
Immunohistochemistry
Frozen 6-mm sections were prepared from skin biopsies. Sections were
fixed in acetone, blocked with mouse IgG, and stained with the following
Abs: biotin-mouse anti-human SLPI (Abcam), rabbit–anti-human HNE
(Athens Research and Technology), rabbit–anti-human LL37 (Innovagen),
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or allophycocyanin–anti-BDCA2 (Miltenyi Biotec), followed by PE–
streptavidin (BD Pharmingen) and allophycocyanin–goat anti-rabbit IgG
F(ab)2 (Jackson ImmunoResearch Laboratories). The sections were
counterstained with Hoechst 33258 (Invitrogen). Purified neutrophils were
seeded on poly-L-lysine–coated coverslips (2–5 3 105 cells/coverslip) and
incubated at 37˚C, 5% CO2 for 30 min in serum-free RPMI 1640 medium.
Cells were then stimulated with 20 nM PMA or 10% serum from patients
suffering from acute psoriasis in RPMI 1640 medium for 3.5 h. Cells were
washed with PBS, fixed with 3.7% formaldehyde for 10 min, and blocked
overnight with 5% FBS, 1% BSA, 0.05% Tween, and 2 mM EDTA in PBS
at 4˚C. Cells were treated with 0.1% saponin in PBS for 30 min at room
temperature and stained in the presence of 0.1% saponin as described
above. Images were captured with a fully motorized fluorescence micro-
scope (NIKON, Eclipse) and analyzed by NIS elements software (Nikon).
Results
SLPI colocalizes with NET components in activated
granulocytes
We first asked whether SLPI is a NET component (e.g., whether
SLPI colocalizes with DNA deposits). Circulating neutrophils were
purified to homogeneity from healthy and psoriasis donors fol-
lowing stimulation with PMA, one of the strongest stimuli for NET
formation. Upon treatment with PMA, ∼30% of neutrophils form
NETs (13). Resting neutrophils and neutrophils treated with PMA
for 3.5 h were fixed and subjected to immunocytochemistry.
In resting neutrophils, mainly granular staining of SLPI was ob-
served (Fig. 1A). Following PMA activation, neutrophils from
both healthy donors and psoriasis patients formed NETs com-
posed of DNA and HNE (Fig. 1B; data not shown). Interestingly,
PMA-activated neutrophils also displayed reactivity with anti-
SLPI mAb. Although the pattern of SLPI distribution differed
from that of DNA/HNE complexes, extracellular SLPI localized in
close proximity to DNA/HNE and in some cases colocalized with
emerging NETs (Fig. 1B). We did not observe a substantial dif-
ference in NET formation or in the decoration of NETs with SLPI
when neutrophils from healthy or psoriasis donors were examined
(data not shown).
The level of SLPI associated with NETs might depend on the
mode of neutrophil activation. Neutrophils treated with sera from
psoriasis patients displayed more SLPI associated with NETs
compared with PMA-stimulated cells (Fig. 1C). In general, sera
from normal individuals, in contrast to sera from psoriasis
patients, did not cause NET release (only one of six normal versus
five of six psoriatic sera caused NET release, and in each case
NETs were decorated with SLPI). In some cases, SLPI colocalized
with extrusions of nuclear material released by neutrophils fol-
lowing incubation with sera from normal donors (Supplemental
Fig. 1). However, in these cases, staining for SLPI was never as
intense as in neutrophils treated with psoriatic sera, suggesting
that sera of psoriasis patients contains a specific factor or factors
capable of triggering SLPI-competent NET release. Because the
incubation of NETs formed by PMA-treated neutrophils with
psoriatic sera produced no or at most weak SLPI immunoreac-
tivity (data not shown), these data suggest that neutrophil-derived
SLPI but not serum-originating SLPI is retained on NETs fol-
lowing stimulation of neutrophils with psoriatic sera.
Neutrophil infiltrates are a hallmark of psoriasis. Moreover,
similar to SLE and small-vessel vasculitis, neutrophils were re-
cently shown to form NETs in psoriatic skin (33). Therefore, we
next investigated whether SLPI is a NET component in vivo by
immunofluorescence analysis of psoriatic skin lesion sections. As
demonstrated in Fig. 2A, in acute psoriasis, SLPI staining mostly
colocalized with HNE+ cells within inflammatory infiltrates.
These cells were also positive for CatG (data not shown), indi-
cating that SLPI-specific immunoreactivity is predominantly in
neutrophils. In some preparations, keratinocytes stained positive
for SLPI (Fig. 2A) in accordance with a previous reports (5).
Notably, SLPI was also clearly present on HNE-positive extra-
cellular DNA deposits (Fig. 2B), indicating that NETs that are
formed in psoriatic skin are decorated with SLPI. Interestingly,
although the distribution and intensity of SLPI and LL37 staining
in neutrophils was comparable, SLPI colocalized with NETs
more frequently than NETs colocalized with LL37 (Supplemental
Fig. 2).
Taken together, these data suggest that NETs decorated by SLPI
may contribute to the pathogenesis of psoriasis.
pDCs colocalize with neutrophils and SLPI-decorated NETs in
psoriatic skin
pDCs are key effectors of the innate immune system important in
the initiation and/or maintenance of psoriasis (22). Although pDCs
and neutrophils are both known to infiltrate psoriatic skin, their
location relative to one another in situ in psoriatic skin and thus
their potential for cross-talk remain unknown. Therefore, we an-
alyzed biopsies of neutrophil-infiltrated psoriatic skin for pDCs.
As demonstrated in Fig. 2C, pDCs were found associated with
SLPI+ neutrophils in lesional skin, in some cases with obvious
colocalization of NETs decorated with SLPI. SLPI+ cells were
also positive for HNE and/or CatG, confirming their identification
as neutrophils (data not shown). Generally, neutrophils were more
abundant than pDCs. Nearly half of all skin-infiltrating pDCs were
located in close proximity to SLPI+ neutrophils, whereas one of
FIGURE 1. SLPI is released from activated granulocytes in vitro.
Fluorescence microscopy analysis of neutrophils isolated from peripheral
blood of normal (A, C) or psoriasis (B) donors. Granulocytes were left
untreated (A), activated with 20 nM PMA (B), or activated with 10% serum
from a psoriatic donor (C) for 3.5 h and stained to detect HNE (red), SLPI
(green), and DNA (blue). Scale bar, 10 mm. Data are from two different
donors in each row and are representative of at least five donors. (A)
Untreated neutrophils show granular staining for SLPI and HNE. Single
SLPI+ and HNE2 eosinophils are indicated by an asterisk. (B) NETs re-
leased by a fraction of the PMA-treated neutrophils contain DNA and HNE
(combined images of red and blue). Most of the cells have unchanged
nuclei (blue), whereas in some cells, the nuclei are in the process of losing
their lobules (arrows). Extracellular SLPI is visible as granular punctate
staining (arrowheads), sometimes clearly associated with HNE and DNA.
(C) Most of the NETs released by neutrophils following treatment with
psoriatic serum contain DNA, HNE, and SLPI (combined images of blue,
red, and green).
The Journal of Immunology 1613
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five pDCs were in direct contact with SLPI+ neutrophils (Table I;
n = 5 independent donors). Thus, neutrophil-derived, SLPI-
competent NETs are in many cases well-positioned to activate
adjacent pDCs in psoriatic lesions.
Production of IFNI by pDCs is stimulated by a complex of DNA
with HNE and SLPI via TLR9
pDCs are considered key players in psoriasis via their production
of IFNI. To determine whether SLPI is capable of triggering pDCs
to synthesize IFNI, we used magnetic bead-selected blood pDCs
from normal donors and treated the cells for 24 h with SLPI or com-
plexes of the SLPI with HNE and DNA isolated from human blood
neutrophils. As demonstrated in Fig. 3A, when tested indepen-
dently, SLPI, HNE, and DNA did not effectively stimulate IFNI
production by human blood pDC. Furthermore, SLPI in complex
with either HNE or DNA did not trigger pDC activation. However,
the trio complex of SLPI, HNE, and DNA triggered a significant
increase in IFNI production by pDCs (∼64-fold increase over
untreated pDCs). As low as 0.1 mM HNE and SLPI in combina-
tion with 2 mg DNA effectively stimulated pDCs, but the com-
bination of HNE and SLPI was most efficient when both
components were used at 1–3 mM together with 2 mg DNA (Fig.
3A; data not shown).
Interestingly, HNE/SLPI/DNA complexes were more potent
compared with LL37/DNA tested under similar experimental
conditions (Fig. 3A). This was manifested in the stronger response
elicited by the HNE/SLPI/DNA mixture compared with LL37/
DNA complexes used at optimal concentration (1 mM SLPI and
HNE versus 10 mM LL37). Moreover, there was no obvious
synergistic or additive effects between LL37 and HNE/SLPI in the
stimulation of IFNI production in complex with DNA (data not
shown), suggesting that LL37 and SLPI may operate indepen-
dently of each other.
We next asked whether particular structural and functional
features of HNE and SLPI were required for pDC activation by
replacing the components with functional or nonfunctional analogs.
HNE was replaced with human neutrophil-derived azurocidin,
which is structurally similar to HNE but lacks proteinase activity
because of mutations in the catalytic triad (34). SLPI was replaced
with a1-PI, an inhibitor of HNE also expressed by neutrophils (4,
35). To discriminate between the enzymatic and nonenzymatic
Table I. pDCs interact with SLPI+ neutrophils in psoriatic skin
Patient
% of pDC in Close
Proximity to SLPI+ Cells
% of pDC in Direct Contact
with SLPI+ Cells
1 60 20
2 30.3 39.4
3 47.8 18.8
4 22.8 12.3
5 45 25
Mean 6 SD 41.2 6 14.7 23.1 6 10.2
For each patient, 5–20 different high-power fields from one section were ana-
lyzed. The total number of BDCA-2–expressing cells, the number of BDCA2+ cells
in close proximity to SLPI+ cells (e.g., cells indicated by arrows in left panel of Fig.
1C), or BDCA2+ cells in direct contact with SLPI+ cells (e.g., cells indicated by
arrows in right panel of Fig. 1C) were counted for each field. The indicated fractions
of pDCs are shown as a percentage of total BDCA2+ cells with mean6 SD in the last
row.
FIGURE 2. pDCs colocalize with
SLPI+ neutrophils and NETs in
lesional psoriatic skin. Frozen sec-
tions of lesional skin biopsies were
stained for HNE (red) and SLPI
(green), with Hoechst counterstain to
detect DNA (blue) (A, B), or were
stained to detect pDCs (BDCA2+,
red) or SLPI+ neutrophils (green),
with Hoechst counterstain (blue) (C).
(A) SLPI-containing HNE+ neu-
trophils in a psoriasis plaque. (B)
Extracellular fibrous material, re-
leased by a fraction of the infiltrating
cells, contains DNA, HNE, and SLPI
(combined images, arrows). (C) Ar-
rows indicate pDCs, whereas arrow-
heads indicate neutrophils at a differ-
ent stage of NET formation. Data in
(A) are from one donor and (B) and
(C) are from two donors and are rep-
resentative of at least five donors.
Scale bar, 100 mm [(A), left column]
and 10 mm [(A), right column and (B)
and (C)].
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effects of HNE, the proteinase was pretreated with a selective
inhibitor (3,4-dichloroisocoumarin) followed by dialysis. To dis-
tinguish the inhibitory and non-inhibitory role of SLPI, SLPI was
oxidized with N-chlorosuccinimide (NSC), which decreases its
HNE inhibitory capacity (30). Alternatively, SLPI was pretreated
with 10 molar excess of neutralizing anti-SLPI Abs. Although
HNE/SLPI/DNA stimulated significant IFNI production by pDCs,
a mixture of DNA with azurocidin and SLPI, or a1-PI and HNE,
had no effect. Likewise, replacement of active HNE with enzy-
matically inactive HNE did not stimulate pDC production of IFNI
(Fig. 3B). Conversely, the reduction of anti-HNE function of
SLPI, either by inhibitor oxidation with NCS or by treatment with
neutralizing Abs, did not impair IFNI production by the stimulated
pDCs (data not shown). Because the indicated treatment reduced
the inhibitory activity of SLPI against HNE by 50–70%, these data
suggest that SLPI does not require HNE inhibitory activity to
stimulate pDCs. However, it is possible that the remaining in-
hibitory activity of SLPI against HNE was necessary and sufficient
to contribute to pDC-stimulated IFNI production.
Taken together, these results likely suggest that enzymatically
active HNE, noninhibitory SLPI, and DNA are required for pDC-
stimulated IFN production.
One of the DNA sensors expressed by pDCs and critically in-
volved in the production of IFNI is TLR9 (21). To determine
whether the effect of SLPI IFNI production was TLR9 mediated,
the cells were pretreated with a TLR9 antagonist, inhibitory oli-
gonucleotide ODNTTAGGG, which acts by disrupting the colo-
calization of stimulatory oligonucleotides with TLR9 in endo-
somal vesicles. As demonstrated in Fig. 3C, ODNTTAGGG but
not control ODN significantly inhibited the effect of the HNE/
SLPI/DNA complexes, indicating that TLR9-mediated signaling
accounts for the majority of the complex activity. Thus, TLR9 is
required for SLPI-dependent activation of pDCs.
Discussion
In this paper, we identified a previously unappreciated role for SLPI
in converting inactive HNE-decorated extracellular DNA into a
trigger for TLR9-dependent IFNI production by pDCs. We also
demonstrated colocalization of neutrophils and pDCs in situ in skin
of psoriasis patients and identified neutrophils as a source of SLPI-
competent DNA structures in lesional skin. The presence of en-
dogenous DNA in the vicinity of immune sensors of nucleic acids,
such as pDCs, might have profound consequences for initiating
psoriasis-relevant cell responses, provided that the DNA can reach
intracellular TLR9. On the basis of our findings, we propose a
model in which: 1) NETs formed by activated neutrophils and
decorated by SLPI are deposited in involved skin; and 2) SLPI as
a NET component stimulates the proinflammatory function of
pDCs, leading to the initiation/augmentation of psoriasis through
production of IFNI. Recent data indicate that the ability of pDCs to
either trigger a proinflammatory response or promote wound repair
are both linked to production of IFNI (21, 36). Therefore, acti-
vation of pDCs by SLPI-decorated NETs might lead to develop-
ment of skin lesions and/or support healing of injured skin.
Alternatively or in addition to a pathogenic role in psoriasis, SLPI-
competent NETs may contribute to wound repair in damaged
psoriatic skin by stimulating pDCs to produce IFNI.
Several studies implicate pDC-derived IFNI as important con-
tributors to psoriasis. Psoriatic skin has a strong IFNI transcrip-
tional fingerprint (e.g., activation of numerous IFNI-inducible
genes (37, 38)). Moreover, psoriasis patients receiving IFNI
therapy for unrelated conditions can develop exacerbated psoriasis
symptoms (39, 40). Direct evidence for a pathogenic role for
pDCs and IFNI in psoriasis is provided by a human/mouse skin
xenograft model in which uninvolved skin of psoriasis donors is
transplanted onto AGR129 mice that are deficient in recombi-
nation activating gene 2 and type I and II IFN receptors. In this
model, the spontaneous conversion of uninvolved skin into pso-
riatic skin lesions is prevented by blocking IFNI signaling or
inhibiting pDC production of IFNI, indicating that pDC-derived
IFNI is critical to drive the development of this skin condition
(22). Therefore, by activating pDCs to produce IFNI, SLPI-
decorated NETs might contribute to breaking tolerance to self-
DNA and induce autoimmune-like psoriasis.
In contrast, in a mechanical skin injury model based on tape-
stripping of mouse skin, wound reepithelization of injured skin
FIGURE 3. SLPI-competent DNA structures stimulate pDC to express
IFNI in a TLR9-dependent manner. Purified pDCs were stimulated with the
indicated factors, which were added directly into pDC cultures, or first
premixed with DNA or with each other. Final concentrations of the factors
was as follows: 2 mg/ml DNA, 1 mM HNE, 3,4-dichroloisocoumarin-inac-
tivated HNE (dicHNE), azurocidin (Azuro), and SLPI, and 10 mM LL37.
TLR9 inhibitor ODNTTAGGG or a control ODN were preincubated with
pDCs at 7.5 mM for 30 min followed by addition of an equal volume of
RPMI 1640 medium containing a HNE/SLPI/DNA mixture prepared as
described above. Supernatants of stimulated pDCs were collected and IFNI
levels determined by ELISA. IFNI synthesis is displayed as pg/ml. Each
data point represents one experiment, and the mean value in each group n =
3–9 is indicated by the horizontal line. Student t test, **p, 0.01, *p, 0.05.
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is significantly impaired following depletion of pDCs, or in mice
deficient in IFNI receptor (36), identifying an important role for
pDC-derived IFNI in promoting wound repair. Because skin of
psoriasis patients shows features of skin injury accompanied by
skin healing, SLPI-competent NETs might play a role in regu-
lating wound repair in psoriatic skin. Notably, pDCs in both
lesional skin of psoriasis patients and mechanically-wounded skin
seem to be activated by a similar mechanism. Recognition of re-
leased nucleic acids by intracellular TLR7 and TLR9, a process
facilitated by cathelicidin peptides such as LL37, is reported to
underlie activation of pDCs to produce IFNI (21, 36). However,
although cathelicidin peptides are sufficient to stimulate pDCs
they also seem to play a redundant role in this process, because the
production of IFNI by pDCs is induced in wounded skin in the
absence of cathelicidins (36). Other factors might convert extra-
cellular DNA into a stimulator for TLR9 in skin-recruited pDCs.
On the basis of our findings, it is tempting to speculate that SLPI
plays a compensatory role in stimulation of TLR9 by DNA
deposits in these cells. This would be consistent with impaired
wound healing observed in SLPI-deficient mice (41). Moreover, as
reported in this work, the lack of cooperation between cathelicidin
peptide LL37 and SLPI in DNA-mediated pDC activation might
also illustrate the redundancy of this pathway for production of
IFNI by pDCs in damaged skin.
Interestingly, cathelicidin hCAP-18 (cationic antimicrobial
peptide of 18 kDa), the LL37 precursor protein, is stored in sec-
ondary granules of PMNs similar to SLPI (2, 25). SLPI and LL37
might therefore both be available at the same time to become
components of emerging NETs. However, in contrast to SLPI,
hCAP 18 requires processing by proteinases stored in primary
granules to release the 37-aa LL37 peptide, which likely occurs
extracellularly (26). Thus, although the LL37-precursor and SLPI
are present in the same neutrophil granules, the formation of
SLPI- or LL37-decorated NETs may not occur at the same time or
in the same NET structure, depending on the extracellular regu-
lation of LL37 processing. This may further support potentially
redundant roles for these structures in activation of TLR9 sig-
naling in pDCs.
Neutrophils that infiltrate both psoriasis and mechanically in-
jured skin might provide the key source of SLPI-decorated ex-
tracellular DNA in the form of NETs. Although our data clearly
indicate that such structures are present in lesional skin of patients
suffering from psoriasis, it remains to be determined when and how
SLPI associates with DNA.
In conclusion, cross-talk between neutrophils and pDCs through
SLPI-decorated NETs offers a novel view on the potential mech-
anism underlying immune responses in psoriasis.
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Supplementary Figure 1. Fluorescence microscopy analysis of neutrophils isolated from peripheral 
blood of normal donors. Granulocytes were left untreated (control), or were activated with 10% serum 
from indicted heterologous donors for 3.5h, and stained to detect HNE (red), SLPI (green) and DNA 
(blue). Scale bar=100 µm (A) or 10 µm (B). Data in A and B are from two donors and are 
representative of five donors treated with one out of four different normal and four different psoriatic 
sera.
Supplementary Figure 2. Immunofluorescence analysis of NET-forming neutrophils stained with 
LL37-specific antibody, SLPI-specific antibody and DNA stained with Hoechst dye. Data are from 
skin of one donor with acute psoriasis and are representative of at least five donors.  Scale bar =10 µm.
